A tumor growth inhibition model based on M-protein levels in subjects with relapsed/refractory multiple myeloma following single-agent carfilzomib use

Authors

F. Jonsson, Pharsight
Y. Ou, Onyx Pharmaceuticals, Inc.
L. Claret, Pharsight
D. Siegel, John Theurer Cancer Center
S. Jagannath, Mount Sinai Medical Center
R. Vij, Washington University School of Medicine in St. Louis
A. Badros, University of Maryland at Baltimore
S. Aggarwal, Onyx Pharmaceuticals, Inc.
R. Bruno, Pharsight

Journal

CPT: Pharmacometrics & Systems Pharmacology

Publication Date

2015

Volume

4

Issue

12

Inclusive Pages

711-719

Document Type

Open Access Publication

DOI

10.1002/psp4.12044

Rights and Permissions

Jonsson, F., Ou, Y., Claret, L., Siegel, D., Jagannath, S., Vij, R., Badros, A., Aggarwal, S. and Bruno, R. (2015), A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use. CPT: Pharmacometrics & Systems Pharmacology, 4: 711–719. doi: 10.1002/psp4.12044 Copyright 2015 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Recommended Citation

Jonsson, F.; Ou, Y.; Claret, L.; Siegel, D.; Jagannath, S.; Vij, R.; Badros, A.; Aggarwal, S.; and Bruno, R., "A tumor growth inhibition model based on M-protein levels in subjects with relapsed/refractory multiple myeloma following single-agent carfilzomib use." CPT: Pharmacometrics & Systems Pharmacology. 4, 12. 711-719. (2015).
https://digitalcommons.wustl.edu/open_access_pubs/4535